Moreover, GPC1-positive EV levels correlated with tumour burden and the patients’ survival and were shown as a prognostic marker superior to CA 19-9, the serum biomarker currently employed in pancreatic cancer screening [266]. This evidence concerns the gene GPC1 and neoplasm.